Skip to content



The Teosyal ® range includes reticulated and non-reticulated gels, as well as gels with or without anaesthetic (lidocaine). An exhaustive product list is available on the website:

Products in the Teosyal ® range are viscoelastic gels of cross-linked hyaluronic acid (except for Teosyal ® Meso and Teosyal ® Redensity [ I ]), sterile, of non-animal origin, to be injected in the dermis. They are designed for filling wrinkles and lines, correcting the facial oval and/or increasing lip volume. Reticulated products in the TEOSYAL ® range have a 6 to 18 months’ duration. This mean duration depends on several factors: the patient’s skin type, the severity of the wrinkle to be corrected, the injection zone and the volume injected. Teosyal ® Meso and Teosyal ® Redensity [ I ] non-cross-linked hyaluronic acid gels are designed to improve skin hydration and radiance.

Your practitioner will help you to choose the product for injection according to your aesthetic requirement.


• Pregnant or breast-feeding woman;

• History of hypersensitivity to one of the components of the products tested (hyaluronic acid, lidocaine, vitamins);

• History of autoimmune disease or disease affecting the immune system (type I diabetes, polyarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, thyroid disorder, scleroderma, inflammatory intestinal disease, lupus, multiple sclerosis, ulcerative colitis);

• Pathology (herpes, acne, rosacea) or unhealed skin alteration;

• Complications after a surgery during the past 5 years

• Previous injection of permanent products (silicone, acrylic polymers, dextran);

• Untreated infectious periodontitis, cellulitis of dental or ENT origin, dental abscess untreated or treated less than one week ago.


• Dissatisfaction with the expected aesthetic result;

• Redness, bruising, ecchymosis, hepatomas, oedema, itching, mild pain at the injection point which may occur after the injection and is resorbed after 24 hours to 8 days (on average within 72 hours);

• Indurations or nodules which may occur at the injection point 15 days to 3 months after the injection;

• Rare reversible colouring of the injection zone.